07:35 AM EDT, 10/24/2025 (MT Newswires) -- Eli Lilly ( LLY ) and Incyte ( INCY ) said Friday their pill Olumiant helped many adolescents aged 12 to 18 years with severe alopecia areata regrow scalp hair after one year in a late-stage study.

Among severely affected teens, 71% on the 4 mg dose achieved "successful" scalp regrowth at one year, and 41% reached near complete regrowth, according to the companies.

Eyebrow and eyelash growth also improved, and safety was consistent with prior experience, with common events like acne and colds, and no major heart or clotting events, the companies said.

Lilly plans to seek a label update to include adolescents and will expand its pediatric study to children ages 6 to under 12, it said.

Shares of Incyte ( INCY ) were up over 1.5% in recent Friday premarket activity.